Evommune, Inc. (EVMN)
NYSEHealth CareBiotechnologySnapshot 2026-10-15
NYSEHealth CareBiotechnologySnapshot 2026-10-15
Research Workspace
Put EVMN beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar broken — Achieve at least $13 million revenue in 2026: Revenue: $0.
View ThesisMiddle-of-the-pack management execution.
View ManagementExpectations look high — what the market is pricing in runs ahead of what analysts forecast.
View ValuationThis stock is volatile — it swings about 3% on a typical day and fell roughly 82% in its worst 12-month stretch.
View RiskEvommune’s case rests on advancing EVO756 Phase 2b data in atopic dermatitis and migraine, but its trial missed the primary endpoint. Recent financial performance is weak, and Q2 FY2026 earnings missed expectations. Revenue growth cannot be established from the desk’s latest earnings data. EVMN trades at 1× sales versus a 10× peer median, while the market prices in more growth than our forecast. The bear case is concrete: the 2026 revenue pillar is broken, and our model puts next-quarter miss risk near 56%. Peer multiples imply a price about 73% above where it trades. The thesis has broken, and this read is provisional.
Trailing returns as of 2026-10-16. EVMN is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 12 analysts currently covering EVMN (as of Oct 2026).
Based on 6 Wall Street analysts offering 12-month price targets for EVMN in the last 4 months.
Continue this research
Compare EVMN with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| EVMN Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 1 valuation methods, at three horizons. As of 2026-10-15. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put EVMN next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Threatens: Advance EVO756 Phase 2b Data in Atopic Dermatitis and Migraine
Trial setback impacts advancement of EVO756 Phase 2b data.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-16. EPS is implied from price ÷ P/E. Not investment advice.
Current $5.17
The last 12 months of price, then the range of analyst 12-month targets from today’s $5.17.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.

Threatens: Advance EVO756 Phase 2b Data in Atopic Dermatitis and Migraine
Trial missing primary endpoint undermines key product advancement objective.
